Publication Name	World Journal of Gastrointestinal Oncology
Manuscript ID	30551
Country	Norway

Received	2016-10-08 08:45
Peer-Review Started	2016-10-10 11:35
To Make the First Decision	2016-11-11 09:35
Return for Revision	2016-11-15 18:10
Revised	2016-11-25 19:40
Second Decision	2016-12-21 11:34
Accepted by Journal Editor-in-Chief	2016-12-21 21:06
Accepted by Company Editor-in-Chief	2016-12-28 15:41
Articles in Press	2016-12-28 15:41
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2017-03-07 09:27
Publish the Manuscript Online	2017-03-09 16:18

ISSN	1948-5204 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Editorial
Article Title	Can molecular biomarkers replace a clinical risk score for resectable colorectal liver metastasis?
Manuscript Source	Invited Manuscript
All Author List	Torhild Veen and Kjetil Søreide
Funding Agency and Grant Number
Corresponding Author	Kjetil Søreide, MD, PhD, Professor, Consultant Surgeon, Department of Gastrointestinal Surgery, HPB Unit, Stavanger University Hospital, P.O. Box 8100, N-4068 Stavanger, Norway. ksoreide@mac.com
Key Words	Colorectal cancer; Liver metastasis; KRAS; Disease-free survival; Circulating tumor cell; Liver surgery; Overall survival; Molecular biomarkers
Core Tip	As a general rule, “good” colorectal liver metastasis (CRLM) cases amenable for surgery have fewer bad genetic traits, such as less likelihood for BRAF mutations or KRAS mutations. KRAS mutation in patients with resectable CRLM suggests a more aggressive disease with shorter progression free and overall survival. Emerging evidence suggest that tumors change during the course of treatment and, thus giving way to new clones that may be of a different genetic makeup and have a different resistance pattern. Thus, new ways of monitoring disease and markers of progression is needed, including circulating cancer biomarkers and tissue-based genetic profiles.
Publish Date	2017-03-09 16:18
Citation	Veen T, Søreide K. Can molecular biomarkers replace a clinical risk score for resectable colorectal liver metastasis? World J Gastrointest Oncol 2017; 9(3): 98-104
URL	http://www.wjgnet.com/1948-5204/full/v9/i3/98.htm
DOI	http://dx.doi.org/10.4251/wjgo.v9.i3.98

Full Article (PDF)	WJGO-9-98.pdf
Full Article (Word)	WJGO-9-98.doc
Manuscript File	30551-Review.docx
Answering Reviewers	30551-Answering reviewers.pdf
Audio Core Tip	30551-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	30551-Conflict-of-interest statement.pdf
Copyright License Agreement	30551-Copyright assignment.pdf
Peer-review Report	30551-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	30551-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	30551-Scientific misconduct check.pdf
Scientific Editor Work List	30551-Scientific editor work list.pdf